Treatment of hepatitis C infections in the era of direct-acting antivirals (DAAs)].

Untreated chronic hepatitis C infection can lead to severe and potentially fatal liver-associated complications. Therefore, every hepatitis C virus (HCV) infection represents an indication for antiviral treatment. In particular, patients with progressive liver disease should be treated urgently. Here, we review indication for treatment as well as goals and basic principles of antiviral therapy. In addition, different treatment regimens and monitoring of the treatment course and outcome are discussed.Today, the treatment of chronic HCV infection is based on interferon-free regimens combining different direct-acting antivirals (DAAs), where the choice of DAA-regimen depends on the viral genotype, previous treatments, and the state of liver fibrosis. With these regimens, equally high virus eradication rates are achievable in patients with compensated liver cirrhosis and in patients without advanced liver disease. In addition, patients with decompensated liver cirrhosis or patients with end-stage renal failure requiring renal replacement therapy, as well as children from an age of 3 years, can be treated safely and highly efficiently with DAA-containing regimens. Physicians should be aware of possible drug interactions of the DAAs with concomitant administered drugs. However, possible interactions can be checked easily online. Although, there is an improvement of prognosis after HCV eradication, patients with advanced liver fibrosis or liver cirrhosis must be included in a lifelong HCC surveillance program. © 2022. The Author(s).

Citation

Kai-Henrik Peiffer, Stefan Zeuzem. Treatment of hepatitis C infections in the era of direct-acting antivirals (DAAs)]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2022 Feb;65(2):246-253

Mesh Tags

Substances

PMID: 35006288

search → result